A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission

References

• Lu PH, Negrin RS. A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–96.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49.
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116:78–86.
   PubMed Web of Science ®Google Scholar
• Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318–27.
   PubMed Web of Science ®Google Scholar
• Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schontube M, . Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant. 1995;15:33–9.
   PubMed Web of Science ®Google Scholar
• Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, . Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer. 2006;119:1377–82.
   PubMed Web of Science ®Google Scholar
• Marten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, . Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica. 2001;86:1029–37.
   PubMed Web of Science ®Google Scholar
• Niam M, Linn YC, Fook CS, Lim TJ, Chu S, Choong A, . Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol. 2011;39:897–903.
   Google Scholar
• Ott PA, Berner BR, Herzog BA, Guerkov R, Yonkers NL, Durinovic-Bello I, . CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J Immunol Methods. 2004;285:223–35.
   PubMedGoogle Scholar
• Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia: definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91:1653–61.
   PubMedGoogle Scholar
• Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, . Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701–7.
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, . Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107:4532–9.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, . A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541–8.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, . Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885–90.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, . Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236–42.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, . RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111:1357–65.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, . Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA. 2010;107: 13824–9.
   PubMed Web of Science ®Google Scholar
• Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, . Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657–62.
   PubMed Web of Science ®Google Scholar
• Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, . Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009;115:3924–34.
   PubMed Web of Science ®Google Scholar
• Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, . Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009;114:1736–45.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, . Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant. 2004;33: 53–60.
   PubMed Web of Science ®Google Scholar
• Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011;118: 3301–10.
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau SK, Liu BH, Ng LH, Yong HX, Hui KM. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology. 2009;126: 423–35.
   PubMed Web of Science ®Google Scholar
• Pievani A, Belussi C, Klein C, Rambaldi A, Golay J, Introna M. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood. 2011;117:510–18.
   PubMed Web of Science ®Google Scholar
• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, . Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007; 92:952–9.
   PubMed Web of Science ®Google Scholar
• Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, . The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant. 2012. Epub page 1–10
   Google Scholar
• Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181–7.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, . Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999;81:1009–16.
   PubMed Web of Science ®Google Scholar
• Jiang H, Liu KY, Tong CR, Jiang B, Lu DP. The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia. Zhonghua Nei Ke Za Zhi. 2005; 44:198–201.
   Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233–40.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, . Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res. 2009; 15:4499–507.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells. J Clin Invest. 2005; 115: 1616–26.
   PubMed Web of Science ®Google Scholar